Gh Research Plc · NASDAQ:GHRS
Gh Research — Investor Presentation (August 2026)
19 slides from Gh Research's investor presentation, Aug 6, 2026
Slide 1: Ultra-Rapid, Durable Remission in TRD
Ultra-Rapid, Durable Remission in TRD GH Research PLC (Nasdaq: GHRS) August 2026 1 2026© GH Research PLC
Slide 2: Disclaimer Regarding Forward-Looking Statements
Disclaimer Regarding Forward-Looking Statements Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC (“GH Research”). Nothing contained in this Any statements contained herein that do not describe historical facts are forward-looking statements prese
Slide 3: GH Research at a glance
GH Research at a glance Post-Phase 2b: shortest-acting psychedelic with category-defining TRD data 1 ~11 min psychoactive phase; 57.5% Day 8 remission and 73% at 6 months in OLE completers Spravato-compatible clinic model — GH001 only option with up to 3 treatments per visit 2 Fits Spravato establis
Slide 4: TRD is prevalent and debilitating — remission collapses after two failures
TRD is prevalent and debilitating — remission collapses after two failures ~4m >85% Patients with TRD in the USa of TRD patients FAIL to remit after two or more failed therapies3 STAR*D, Remission rate (%) by prior treatment failures3 ~1 in 3 have a lifetime suicide attempt4 37% TRD population 31% ~
Slide 5: Pipeline
Pipeline Pipeline Product Candidate Indication Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Current Status Milestone Treatment-resistant Phase 2b Phase 3 initiation in depression (TRD) RDBPC completed 2026 GH001 Postpartum Mebufotenin for Phase 2a POC Completed depression (PPD) inhalation administr
Slide 6: Phase 2b Study Primary Endpoint: MADRS Reduction vs Placebo
Phase 2b Study Primary Endpoint: GH001 Led to Mean MADRS Reduction from Baseline of -15.5 on Day 81 vs Placebo (P<0.0001)2 0 0.3 −1.4 −1.5 LS Mean (±SE) Change from Baseline -5 GH001 (n=40) in MADRS Total Score Placebo (n=41) -10 -15 −15.2 -20 −17.8 −18.6 LS mean difference vs placebo: −15.5 (P<0.00
Slide 7: Secondary Endpoints: Remissions, GH001 and Spravato Monotherapy
Secondary Endpoints: Remissionsa GH001 Day 2 and Day 8 and Spravato Monotherapy (84 mg) Day 2, Day 8 and Day 28 Secondary Endpoints: Remissionsa GH001 Day 2 and Day 8 and Spravato Monotherapy (84 mg) Day 2, Day 8 and Day 28 Remission Rates with Spravato 100% Remission Rates with GH0011 100% monother
Slide 8: 73% Remission Rate at 6 Months in OLE Completers
73% Remission Rate at 6 Months in OLE Completers1 73% Remission Rate at 6 Months in OLE Completers1 Double-blind OLE completersa 100 n=40 on GH001 n=63 Percentage of Patients in Remissionc 80 73.0% 60 57.5% 40 20 0 Day 8 Month 6ᵇ Patients who completed the OLE had a mean of four treatment visits, wi
Slide 9: GH001 demonstrates efficacy independent of prior treatment lines in TRD
GH001 demonstrates efficacy independent of prior treatment lines in TRD1 GH001 demonstrates efficacy independent of prior treatment lines in TRD1 GH001 Day 8 GH001 Month 6 STAR*D Reference2 100 100 Mean 100 Mean 90 Remission Rate (MADRS ≤10) (%) Remission Rate (MADRS ≤10) (%) 90 90 85.7 80 80 80 Rem
Slide 10: GH001 is Built for the Interventional Psychiatry Workflow
GH001 is Built for the Interventional Psychiatry Workflow SPRAVATO®1,2 GH0013 Setting Outpatient clinics by qHCPs and clinical staff Outpatient clinics by qHCPs and clinical staff Psychotherapy No mandated psychotherapy No mandated psychotherapy Clinic visit ~2 hours ~1–3 hoursa WHERE GH001 DIFFERS
Slide 11: GH001: Shortest Duration of the Psychoactive Experience of 11 minutes
GH001: Shortest Duration of the Psychoactive Experience of 11 minutes —enables up to 3 treatments per clinic visit GH001: Shortest Duration of the Psychoactive Experience of 11 minutes — enables up to 3 treatments per clinic visit 6-8 hours 8h 7h Duration of Psychoactive Experience 6h (approximate a
Slide 12: GH001: Only psychedelic with 1-3 treatments for highest efficacy and fast relief
GH001: Only psychedelic with 1-3 treatments for highest efficacy and fast relief CLINIC FOOTPRINT TREATMENT(S) WITHIN VISIT DAY 8 REMISSION Cross-trial; not head-to-head GH001 GH001 GH001 1–3 h 1-3 Treatments per visit 75% reach target intensity in 1–2 doses. 57.5% 99% discharge-ready ≤1 h after las
Slide 13: 83% Fewer Treatment Visits with GH001 than with Spravato
83% Fewer Treatment Visits with GH001 than with Spravato® 83% Fewer Treatment Visits with GH001 than with Spravato® GH001 Four visitsa 73% remission at 6 monthsb,d SPRAVATO® 23 visits ICER estimateᶜ,ᵈ 0 5 10 15 20 25 Treatment visits in 6 months 4 vs 23 · ~6× fewer Abbreviations: ICER = Institute fo
Slide 14: Beyond MADRS: Rapid and Durable Multi-Domain Benefit in TRD
Beyond MADRS: Rapid and Durable Multi-Domain Benefit in TRD HAM-A Total Score CGI-S Score Day 8 Month 6 Day 8 Month 6 GH001 Placebo OLE completers GH001 Placebo OLE completers (n=40) (n=41) (n=63) (n=40) (n=41) (n=63) 0 0 100 1.6 5.0 12.5 14.6 7.9 7.5 17.1 6 - Severely ill 4.8 -2 −1.0 -2 % of patien
Slide 15: Beyond MADRS: Anhedonia and Quality of Life Benefit in TRD
Beyond MADRS: Anhedonia and Quality of Life Benefit in TRD MADRS Anhedonia Factor Score Q-LES-Q-SF Total Score Day 8 Month 6 Day 8 Month 6 5 5 OLE GH001 (n=40) Placebo (n=41) 30 30 completers Mean (±SD) Change from Baseline in MADRS (n=63) **** **** 24.8 LS mean change from baseline 0 25 25 0 0.0 20
Slide 16: Rapid MADRS response across TRD, PPD, and BDII + MDE
Rapid MADRS response across TRD, PPD, and BDII + MDE TRD1 PPD2 BDII + MDE3 57.5% remission at Day 8 100% remission at Day 8 33.3% remission at Day 8 5 5 5 GH001 (N=10) GH001 (N=6) Mean (±SD) Change From Baseline in 0 0 0 -1.5 0.3 -1.4 -5 -5 -5 MADRS Total Score -10 -10 -10 -15 -15 -15 -13.3 -15.2 -2
Slide 17: GH001 was well-tolerated in patients with TRD, BDII + MDE, and PPD
GH001 was well-tolerated in patients with TRD, BDII + MDE, and PPD GH001-TRD-201 Study GH001-BD-202 Study GH001-PPD-203 Study Open-Label Double-Blind Part Extension GH001 Placebo GH001 (n=6) GH001 (n=10) GH001 (n=81) (n=40) (n=41) Treatment-Emergent Patients, n Patients, n Treatment-Emergent Event P
Slide 18: Multi-layer IP and regulatory protection into the 2040s
Multi-layer IP and regulatory protection into the 2040s R E G U L AT O R Y E XC L U S I V I T Y FDA 5 years +2.5 years paragraph IV stay EMA 10 years +1 year for a new indication PAT E N T S Earliest patent filings relating to mebufotenin (including pending applications): Novel aerosol compositions
Slide 19: GH Research at a glance
GH Research at a glance Post-Phase 2b: shortest-acting psychedelic with category-defining TRD data 1 ~11 min psychoactive phase; 57.5% Day 8 remission and 73% at 6 months in OLE completers Spravato-compatible clinic model — GH001 only option with up to 3 treatments per visit 2 Fits Spravato establis